AtlasDigestiveUpper digestive system diseases

Gastroesophageal reflux disease

2Disease-modifyingAI-generated

GERD: manageable with drugs, but rarely curedAI-generated

Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251989 — Omeprazole approved (FDA)1995 — Lansoprazole approved (FDA)1999 — Rabeprazole approved (FDA)2000 — Pantoprazole approved (FDA)2001 — Esomeprazole approved (FDA)2006 — Bismuth subcitrate potassium approved (FDA)2009 — Dexlansoprazole approved (FDA)2022 — Vonoprazan approved (FDA)1989
1989: Drug approval — Omeprazole approved (FDA). 1995: Drug approval — Lansoprazole approved (FDA). 1999: Drug approval — Rabeprazole approved (FDA). 2000: Drug approval — Pantoprazole approved (FDA). 2001: Drug approval — Esomeprazole approved (FDA). 2006: Drug approval — Bismuth subcitrate potassium approved (FDA). 2009: Drug approval — Dexlansoprazole approved (FDA). 2022: Drug approval — Vonoprazan approved (FDA)

What's being tested now

2002: 1 trials started2006: 1 trials started2007: 1 trials started2011: 1 trials started2012: 1 trials started2013: 4 trials started2014: 2 trials started2015: 2 trials started2016: 4 trials started2018: 2 trials started2019: 6 trials started2020: 8 trials started2021: 12 trials started2022: 10 trials started2023: 22 trials started2024: 31 trials started2025: 54 trials started2026: 37 trials started20102020202654

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 183 active Gastro Esophageal Reflux trials on Clin2 →

Where we are

AI-generated

Gastroesophageal reflux disease is a chronic condition. Available treatments are disease-modifying but not curative; acid-suppressing drugs heal esophagitis, relieve symptoms, and reduce complications, but most people need ongoing therapy. Surgery can cure a subset, but it is not standard for most. No reliable burden trend data are available, but the trajectory of care has improved since the first H2 blocker, cimetidine, was approved in 1977. More recent drugs and surgical options have expanded control. Research continues, with 167 trials started in the last five years, including eight phase-3 studies, and 183 trials now active.

Can GERD be cured?
For most people, no. Acid-suppressing drugs control symptoms and heal damage while taken, but the condition typically returns without them. Surgery can cure a subset of patients, but it is not the standard approach for the majority.
Will I need medication for life?
Often yes. GERD is chronic, and most patients require ongoing therapy to prevent symptoms and complications like strictures. Some people may reduce doses over time, but that depends on severity and response.
What was the biggest treatment advance?
The approval of cimetidine in 1977 introduced the first H2 blocker, proving that reducing stomach acid could effectively treat reflux. That opened the door to later, more powerful drugs like PPIs.
Are new treatments being developed?
Yes. Over 180 trials are currently active, and 167 have started in the past five years, including late-stage studies. These are exploring better symptom control and possibly approaches that address the underlying reflux mechanism.
Does surgery cure GERD for everyone?
No. Fundoplication can cure reflux in selected patients, but it is not standard for most, and results vary. Some people still need medication after surgery. Candidates are carefully chosen based on anatomy and response to drugs.

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.